New data in bladder cancer could help make Bavencio (avelumab) more than just an also ran in checkpoint inhibition.
The market is led by Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab), with Roche’s (ROG: SIX) Tecentriq (atezolizumab) among the other options to make a major impact.
In terms of revenues, Bavencio has thus far followed far behind, taking in just 103 million euros ($114 million) in 2019, an increase of 44% from the prior year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze